Wall Street analysts forecast that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will report sales of $30.01 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Enanta Pharmaceuticals’ earnings. The lowest sales estimate is $29.51 million and the highest is $30.51 million. Enanta Pharmaceuticals posted sales of $8.96 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 234.9%. The firm is expected to report its next quarterly earnings results on Monday, May 14th.
On average, analysts expect that Enanta Pharmaceuticals will report full year sales of $30.01 million for the current year, with estimates ranging from $136.31 million to $140.71 million. For the next fiscal year, analysts forecast that the business will post sales of $119.40 million per share. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 earnings per share for the quarter, missing analysts’ consensus estimates of $2.13 by ($0.27). The firm had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. The firm’s revenue for the quarter was up 491.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.09) earnings per share.
Hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. grew its stake in shares of Enanta Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock worth $1,930,000 after acquiring an additional 304 shares during the period. Vanguard Group Inc. grew its stake in shares of Enanta Pharmaceuticals by 6.9% in the second quarter. Vanguard Group Inc. now owns 847,021 shares of the biotechnology company’s stock worth $30,475,000 after acquiring an additional 54,856 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Enanta Pharmaceuticals by 1.4% in the third quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after acquiring an additional 7,617 shares during the period. BNP Paribas Arbitrage SA grew its stake in shares of Enanta Pharmaceuticals by 69.1% in the third quarter. BNP Paribas Arbitrage SA now owns 7,456 shares of the biotechnology company’s stock worth $349,000 after acquiring an additional 3,047 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Enanta Pharmaceuticals by 36.7% in the third quarter. Wells Fargo & Company MN now owns 18,197 shares of the biotechnology company’s stock worth $852,000 after acquiring an additional 4,886 shares during the period. Hedge funds and other institutional investors own 67.70% of the company’s stock.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) opened at $77.96 on Wednesday. The firm has a market cap of $1,490.00, a PE ratio of 42.37 and a beta of 1.04. Enanta Pharmaceuticals has a 12 month low of $27.24 and a 12 month high of $95.91.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/02/21/analysts-expect-enanta-pharmaceuticals-inc-enta-will-announce-quarterly-sales-of-30-01-million.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.